ATE276360T1 - Verwendung pharmazeutischer zusammensetzungen zur behandlung von neurodegenerativen krankheiten - Google Patents
Verwendung pharmazeutischer zusammensetzungen zur behandlung von neurodegenerativen krankheitenInfo
- Publication number
- ATE276360T1 ATE276360T1 AT94920987T AT94920987T ATE276360T1 AT E276360 T1 ATE276360 T1 AT E276360T1 AT 94920987 T AT94920987 T AT 94920987T AT 94920987 T AT94920987 T AT 94920987T AT E276360 T1 ATE276360 T1 AT E276360T1
- Authority
- AT
- Austria
- Prior art keywords
- pharmaceutical compositions
- neurodegenerative diseases
- treating neurodegenerative
- new
- interaction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9307962A FR2707880B1 (fr) | 1993-06-30 | 1993-06-30 | Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodégénératives. |
| PCT/FR1994/000771 WO1995001429A1 (fr) | 1993-06-30 | 1994-06-27 | Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodegeneratives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE276360T1 true ATE276360T1 (de) | 2004-10-15 |
Family
ID=9448720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94920987T ATE276360T1 (de) | 1993-06-30 | 1994-06-27 | Verwendung pharmazeutischer zusammensetzungen zur behandlung von neurodegenerativen krankheiten |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6140112A (de) |
| EP (2) | EP1454984A1 (de) |
| JP (1) | JP3755825B2 (de) |
| KR (1) | KR100517879B1 (de) |
| AT (1) | ATE276360T1 (de) |
| AU (1) | AU696644B2 (de) |
| CA (1) | CA2166318C (de) |
| DE (1) | DE69433996T2 (de) |
| DK (1) | DK0707644T3 (de) |
| ES (1) | ES2227528T3 (de) |
| FI (1) | FI120942B (de) |
| FR (1) | FR2707880B1 (de) |
| NO (1) | NO321455B1 (de) |
| PT (1) | PT707644E (de) |
| WO (1) | WO1995001429A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6017903A (en) | 1996-09-27 | 2000-01-25 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors |
| US5824662A (en) | 1996-09-27 | 1998-10-20 | Guilford Pharmaceuticals Inc. | Treatment of global and focal ischemia using naaladase inhibitors |
| CZ60499A3 (cs) | 1996-09-27 | 1999-08-11 | Guilford Pharmaceuticals Inc. | Prostředky s účinkem na NAALADázy, způsoby léčení glutamátové abnormality a způsoby ovlivňování neuronální aktivity u živočichů |
| DE29916160U1 (de) | 1999-09-14 | 2000-03-09 | Cardiogene Gentherapeutische Systeme AG, 40699 Erkrath | Modulation der Transkription von Genen in vaskulären Zellen |
| US6599741B1 (en) | 1999-09-14 | 2003-07-29 | Avontec Gmbh | Modulating transcription of genes in vascular cells |
| CN1315402A (zh) * | 2000-03-28 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人淀粉类前体蛋白结合蛋白14和编码这种多肽的多核苷酸 |
| CN1315439A (zh) * | 2000-03-29 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人淀粉类前体蛋白结合蛋白9和编码这种多肽的多核苷酸 |
| DE10308045B3 (de) | 2003-02-26 | 2004-06-17 | Lurgi Ag | Verfahren und Vorrichtung zur kontinuierlichen Gewinnung freier Weinsäure aus Kaliumhydrogentartrat enthaltenden Rohstoffen |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2573436B1 (fr) * | 1984-11-20 | 1989-02-17 | Pasteur Institut | Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins |
| WO1991011535A1 (en) * | 1990-01-30 | 1991-08-08 | Childrens Hospital Of Los Angeles | Inhibition of transcription by double-stranded oligonucleotides |
| WO1991018088A1 (en) * | 1990-05-23 | 1991-11-28 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Adeno-associated virus (aav)-based eucaryotic vectors |
| FR2675803B1 (fr) * | 1991-04-25 | 1996-09-06 | Genset Sa | Oligonucleotides fermes, antisens et sens et leurs applications. |
| GB9114437D0 (en) * | 1991-07-03 | 1991-08-21 | Health Lab Service Board | Recombinant adenoviruses and the use thereof for detecting the presence in eukaryotic cells of the expression products of specific genes |
| FR2708283B1 (fr) * | 1994-01-14 | 1995-10-20 | Rhone Poulenc Rorer Sa | Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodégénératives. |
-
1993
- 1993-06-30 FR FR9307962A patent/FR2707880B1/fr not_active Expired - Lifetime
-
1994
- 1994-06-27 EP EP04006618A patent/EP1454984A1/de not_active Withdrawn
- 1994-06-27 AU AU71882/94A patent/AU696644B2/en not_active Expired
- 1994-06-27 CA CA002166318A patent/CA2166318C/fr not_active Expired - Lifetime
- 1994-06-27 DK DK94920987T patent/DK0707644T3/da active
- 1994-06-27 AT AT94920987T patent/ATE276360T1/de active
- 1994-06-27 ES ES94920987T patent/ES2227528T3/es not_active Expired - Lifetime
- 1994-06-27 KR KR1019950706050A patent/KR100517879B1/ko not_active IP Right Cessation
- 1994-06-27 JP JP50330895A patent/JP3755825B2/ja not_active Expired - Lifetime
- 1994-06-27 DE DE69433996T patent/DE69433996T2/de not_active Expired - Lifetime
- 1994-06-27 US US08/569,149 patent/US6140112A/en not_active Expired - Lifetime
- 1994-06-27 EP EP94920987A patent/EP0707644B1/de not_active Expired - Lifetime
- 1994-06-27 WO PCT/FR1994/000771 patent/WO1995001429A1/fr active IP Right Grant
- 1994-06-27 PT PT94920987T patent/PT707644E/pt unknown
-
1995
- 1995-12-01 NO NO19954888A patent/NO321455B1/no not_active IP Right Cessation
- 1995-12-29 FI FI956353A patent/FI120942B/fi not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR100517879B1 (ko) | 2005-12-16 |
| FI956353A (fi) | 1995-12-29 |
| AU696644B2 (en) | 1998-09-17 |
| PT707644E (pt) | 2005-01-31 |
| JP3755825B2 (ja) | 2006-03-15 |
| CA2166318C (fr) | 2009-02-10 |
| ES2227528T3 (es) | 2005-04-01 |
| KR960703432A (ko) | 1996-08-17 |
| NO954888D0 (no) | 1995-12-01 |
| CA2166318A1 (fr) | 1995-01-12 |
| EP0707644B1 (de) | 2004-09-15 |
| FI120942B (fi) | 2010-05-14 |
| FR2707880B1 (fr) | 1995-10-06 |
| EP0707644A1 (de) | 1996-04-24 |
| JPH08512043A (ja) | 1996-12-17 |
| FI956353A0 (fi) | 1995-12-29 |
| NO954888L (no) | 1995-12-01 |
| US6140112A (en) | 2000-10-31 |
| DE69433996D1 (de) | 2004-10-21 |
| NO321455B1 (no) | 2006-05-15 |
| DK0707644T3 (da) | 2005-01-17 |
| WO1995001429A1 (fr) | 1995-01-12 |
| DE69433996T2 (de) | 2005-09-22 |
| FR2707880A1 (fr) | 1995-01-27 |
| AU7188294A (en) | 1995-01-24 |
| EP1454984A1 (de) | 2004-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU95115239A (ru) | Аналог эритропоэтина | |
| ES2160707T3 (es) | Composiciones que comprenden agentes deteriorantes del adn y p53. | |
| BR9205640A (pt) | Dímero de apolipoproteína ai-milano, composiçao farmacológica, processo de preparaçao do dímero, uso deste na preparaçao de medicamentos e processo para o tratamento de aterosclerose e doenças cardiovasculares | |
| DE69434820D1 (de) | Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis | |
| DE69230789D1 (de) | Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten | |
| DE69841982D1 (de) | Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie | |
| PT100472A (pt) | Sequencias genomicas do virus da hepatite c e composicoes farmaceuticas que as contem, para diagnostico e terapeutica da hepatite c | |
| DE69233760D1 (de) | Inhibitoren der menschlichen Elastase von Neutrophilen | |
| DE69634698D1 (de) | Gewebespezifische und ziel-rna-spezifische ribozyme | |
| ATE276360T1 (de) | Verwendung pharmazeutischer zusammensetzungen zur behandlung von neurodegenerativen krankheiten | |
| DE69839489D1 (de) | Impfstoff zur vorbeugung bzw. behandlung der hepatitis c | |
| DE68912155D1 (de) | Antivirales Kombinationspräparat. | |
| BR9306207A (pt) | Composiçao farmacéutica e processo para o tratamento de infecçao ou doença causada pelo vírus da hepatite b processo para a preparaçao da composiçao e uso de fiau ou de uma pró-droga ou metabolito do mesmo | |
| FR2701960B1 (fr) | Polyribozyme apte à conférer, aux plantes, une résistance aux virus et plantes résistantes produisant ce polyribozyme. | |
| NO945031D0 (no) | Anvendelse av en hymenopteragift til fremstilling av et medikament for behandling av DNA-virusinfeksjoner | |
| FI961494A (fi) | Farmaseuttisia koostumuksia ja niiden käyttö, etenkin hermoston rappeutumissairauksien hoitamiseksi | |
| ATE209683T1 (de) | Planze resistent gegen mindestens zwei viren und dessen preparation | |
| ATE196424T1 (de) | Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten | |
| ATE65543T1 (de) | Dna-sequenzen des ebv-genoms, rekombinante dnamolek¨le, verfahren zur herstellung von ebvverwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten. | |
| MXPA94003453A (es) | Metodo y composicion para el tratamiento de pacientes con hepatitis b que tienen descompensacion hepatica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0707644 Country of ref document: EP |